JRSIS Health Care Corporation (JRSS) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of JRSIS Health Care Corporation $0.01, price $0.02, upside -4.7%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch JRSIS Health Care Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
JRSIS Health Care Corporation develops and produces medical technology and equipment in the People's Republic of China. The company develops and markets a multi-faceted smart environment for the retail distribution of pharmaceutical products by pharmacies, hospitals, and online distributors.
Show more
JRSIS Health Care Corporation develops and produces medical technology and equipment in the People's Republic of China. The company develops and markets a multi-faceted smart environment for the retail distribution of pharmaceutical products by pharmacies, hospitals, and online distributors. It offers JM-YF-2000 Automatic Medicine Dispenser, which provides intelligent prompts for high-speed facile human-computer interaction to yield prompt dispensing of medications and batch refilling in the user safety environment. The company was founded in 2018 and is based in Yongzhou, the People's Republic of China.
Stock analysis
JRSIS Health Care Corporation (JRSS) currently trades at $0.0150, while our model-based Fair Value estimate is $0.0143, implying the stock looks roughly 4.9% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 12 models at a data quality of 83/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Consumer Cyclical sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
JRSIS Health Care Corporation reported revenue of $320K in FY2025 versus $44.4M in FY2021, a compound −70.9%/yr. Reported net income was $8.8K in FY2025, compounding −74.9%/yr from FY2021.
Key figures
Market cap $2.5M · P/S ratio 0.72 · EPS (TTM) $−0.2900 · Net margin 2.8% · Return on equity −479% · Return on assets (EBIT) −15.8% · Operating margin −92.5% · Revenue growth (YoY) −55.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 88% below its 52-week high and 150% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 4% fair-value upside, at −5%, JRSS screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−75.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−61.0%
Start year 2020 (pandemic). Over 10 years: −30.3% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.5%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−75.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−75.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−76% vs −50%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 3%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 26.9%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare JRSIS Health Care Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Retail · 230 stocks
Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−5% · Below median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−32% · Bottom 25%
Net margin (TTM)−14% · Bottom 25%
Operating margin (TTM)−92% · Bottom 25%
Growth and dividend
Revenue growth−55% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Specialty Retail median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.72× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)27· sector 45
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 27
HEALTH (low debt)0· sector 94
DIVIDEND (yield)0· sector 63
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "JRSIS Health Care Corporation Fair Value". https://www.fairvalue-calculator.com/stock/JRSS
Frequently asked questions
Is JRSIS Health Care Corporation (JRSS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0143 versus a price of $0.0150, about −5% upside (fairly valued).
What is the fair value of JRSS?
Our model-based fair value for JRSIS Health Care Corporation is $0.0143 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.0150.
What is the quality score of JRSS?
JRSIS Health Care Corporation has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JRSIS Health Care Corporation (JRSS)?
Our model-based price target is the fair value of $0.0143 (as of Sep 23, 2026) from 3 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the JRSIS Health Care Corporation stock forecast for 2026?
Our models put fair value at $0.0143, about −5% upside versus a price of $0.0150 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of JRSIS Health Care Corporation (JRSS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JRSIS Health Care Corporation it is $0.0143 per share (as of Sep 23, 2026), against a price of $0.0150. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is JRSIS Health Care Corporation stock overvalued or undervalued in 2026?
As of Sep 23, 2026, JRSS trades above its calculated fair value: price $0.0150, fair value $0.0143, a gap of about −5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JRSS?
No. The price is what the market pays today ($0.0150); the fair value is what the company's own numbers justify ($0.0143). For JRSIS Health Care Corporation the two are $0.0007 per share apart. That gap is exactly why we show both numbers side by side.
How much is JRSIS Health Care Corporation worth?
The market values JRSIS Health Care Corporation at about $2.5M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0150; our models calculate a fair value of $0.0143 per share.
How solid is the balance sheet of JRSIS Health Care Corporation (JRSS)?
Balance-sheet figures for JRSIS Health Care Corporation (as of Sep 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is JRSS from its 52-week high?
JRSIS Health Care Corporation trades at $0.0150, about 88% below its 52-week high of $0.1300 and 150% above the low of $0.0060 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0143 is for.
Which stocks are comparable to JRSIS Health Care Corporation?
From the same area (Consumer Cyclical) we also value Alimentation Couche-Tard Inc, Casey's General Stores, Inc, Williams-Sonoma, Inc, Ulta Beauty, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JRSIS Health Care Corporation stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0150, calculated fair value $0.0143 (−5%), Quality Score 32/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JRSS calculated?
We run JRSIS Health Care Corporation through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0143, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. JRSIS Health Care Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JRSIS Health Care Corporation (JRSS)?
The closing price on Sep 22, 2026 was $0.0150. Our model-based fair value is $0.0143, about −5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JRSIS Health Care Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of JRSIS Health Care Corporation
How large is the market capitalisation of JRSIS Health Care Corporation (JRSS)?
The market capitalisation of JRSIS Health Care Corporation is $2.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JRSIS Health Care Corporation (JRSS)?
The price-to-sales ratio of JRSIS Health Care Corporation is 0.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of JRSIS Health Care Corporation (JRSS)?
Earnings per share at JRSIS Health Care Corporation are $−0.2900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of JRSIS Health Care Corporation (JRSS)?
The net margin of JRSIS Health Care Corporation is 2.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JRSIS Health Care Corporation (JRSS)?
The return on equity (ROE) of JRSIS Health Care Corporation is −479% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JRSIS Health Care Corporation (JRSS)?
On an EBIT basis the return on assets of JRSIS Health Care Corporation is −15.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JRSIS Health Care Corporation (JRSS)?
The operating margin of JRSIS Health Care Corporation is −92.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JRSIS Health Care Corporation (JRSS)?
Revenue at JRSIS Health Care Corporation is growing −55.2% versus a year earlier (3y avg +53.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does JRSIS Health Care Corporation (JRSS) generate?
The free cash flow of JRSIS Health Care Corporation is −$136K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does JRSIS Health Care Corporation (JRSS) hold?
JRSIS Health Care Corporation holds more cash than debt, $30.1K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch JRSIS Health Care Corporation in the live analysis
One click puts JRSIS Health Care Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026